Wisconsin Alumni Research Foundation

Harvard College

Mark Patrick Keller

Alan D Attie

Samuel Helmer Gellman

Alan Saghatelian

Lisa M Johnson

Weiping Tang

Ka Yang

Jan Peter Van Pijkeren

Jee-Hwan Oh

Gabrielle N Winston-McPherson

Michelle Kimple

Haibo Xie

Described are benzoimidazole indolyl methane compounds, pharmaceutical compositions containing them, and use of the compounds to inhibit PCSK9-mediated ailments. The compounds have the structure: 

Benzoimidazole indolyl methanes and methods of using them to inhibit PCKS9 and PCKS9-mediated ailments

Described herein are peptide analogs of glucagon-like peptide 1 (GLP-1) that retain agonist activity, but are more resistant to proteolytic degradation than native GLP-1. In the analogs, at least one &#x3b1;-amino acid found in the native GLP-1 is replaced with a &#x3b2;-amino acid residue, which may or may not be cyclically constrained. Pharmaceutical compositions containing the analogs are described, as are methods to treat diabetes, and methods to make proteolytically resistant GLP-1 analogs.

Alpha/beta-polypeptide analogs of glucagon-like peptide 1

Methods and microorganisms for systemically introducing a polypeptide in the bloodstream of a subject. The methods of the invention include administering into the gastrointestinal tract of a subject a bacterium configured to express and produce and release the polypeptide. The bacterium is administered in an amount effective to introduce the polypeptide in the bloodstream of the subject, preferably in a detectable amount. The microorganisms of the invention include lactic acid bacteria, such as, that comprise a recombinant gene configured to express a polypeptide to be systemically introduced.

Methods for systemically delivering polypeptides and microorganisms therefor

Alpha/beta-polypeptide analogs of glucagon-like peptide-1

Provided herein are methods for increasing insulin secretion from beta cells. Also provide herein are methods comprising administering to a subject in need of increased insulin secretion a composition comprising a compound that directly or indirectly activates adenylate cyclase and an E prostanoid 3 (EP3) receptor antagonist that attenuates G alpha-i-subfamily (GSIS)-mediated adenylate cyclase inhibition.

E-prostanoid receptor, Ptger3, as a novel anti-diabetic therapeutic target

Growing community of inventors

McFarland, WI, United States of America

Mark Patrick Keller